TMCnet News
Research and Markets: US Cancer Vaccine Pipeline AnalysisDUBLIN --(Business Wire)-- Research and Markets (http://www.researchandmarkets.com/research/5mdh5b/us_cancer_vaccine) has announced the addition of the "US Cancer Vaccine Pipeline Analysis" report to their offering. Cancer vaccines are a viable option for treating many types of cancers which in the present day do not have effective treatments. With the approval of the expensive prostate cancer vaccine, Provenge by Dendreon, the field of cancer vaccines has received an unprecedented boost. Consequently, many companies are expected to enter this emerging and highly profitable field of preventing, treating, and potentially curing cancer. Merck's Gardasil, a Prophylactic cancer vaccine, along with GSK's Cervarix are some of the first vaccines to have gained attention globally with their blockbuster status. The market for cancer vaccine is in its growth stage in the US and has great opportunities for entry. Constituting almost 50% of the global pie, the US cancer vaccine market was estimated to be worth USD 14 Billion in 2012. With close to 1.5 million Americans being diagnosed with cancer every year, this market is expected to reach USD 20 billion by 2020. - US Cance Vaccine Pipeline Analysis - gives comprehensive insight on the various vaccines being developed for the treatment of various cancers. Research report covers all vaccines being developed in various development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the US cancer vaccine market based upon development process. Following parameters for each orphan designated drug profile in development phase are covered in - US Cancer Vaccine Pipeline Analysis - research report: - Drug Profile Overview - Alternate Names for Drug - Active Indication - Phase of Development - Mechanism of Action - Brand Name - Patent Information - Orphan Designation by Indication, Country & Organisation - Country for Clinical Trial - Owner / Originator/ Licensee/Collaborator - Administrative Route - Drug Class - ATC Codes US Cancer Vaccine Pipeline by Clinical Phase: - Research: 2 - Preclinical: 38 - Clinical: 2 - Phase-0: 1 - Phase-I: 35 - Phase-I/II: 19 - Phase-II: 32 - Phase-II/III: 2 - Phase-III: 17 - Marketed: 5 Key Topics Covered: US Cancer Vaccine Market Overview US Cancer Vaccine Market Regulations Cancer Vaccine Development Clinical Phase: Research Cancer Vaccine Development Clinical Phase: Preclinical Cancer Vaccine Development Clinical Phase: Clinical Cancer Vaccine Development Clinical Phase: Phase-0 Cancer Vaccine Development Clinical Phase: Phase-I Cancer Vaccine Development Clinical Phase: Phase-I/II Cancer Vaccine Development Clinical Phase: Phase-II Cancer Vaccine Development Clinical Phase: Phase-II/III Cancer Vaccine Development Clinical Phase: Phase-III Marketed List of Tables For more information visit http://www.researchandmarkets.com/research/5mdh5b/us_cancer_vaccine About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. |
